According to the NCBI report, monoclonal antibodies (mABs) have been considered as an innovative technology for the treatment of some types of cancer, as they possess the capability of targeting and selectively killing tumor cells. For example, there was a retrospective analysis conducted based on consultation of the Brazilian Health Regulatory Agency (Anvisa) where these mABs were characterized according to the target antigen, type of antibody, year of registration, therapeutic indications, and applicant. For records, in August 2021, Anvisa announced granting of emergency use authorization (EUA) for Celltrion’s “Regdanvimab (CT-P59)” for treating adults with mild-to-moderate COVID-19 and who do not require supplemental oxygen and are at higher risk of progression to severe COVID. As Brazil had the highest number of confirmed cases from COVID-19 in South and Central America with an average 35,000 cases per day and since the beginning of pandemic, at least 1 in 10 residents have been infected a total of 20,249,176 reported severe cases. Therefore, Celltrion’s monoclonal antibody-based product significantly reduces the risk of COVID-19 related hospitalization and deaths by 72% for patients at higher risk of progression to severe COVID-19 and 70% of all patients. Therefore, amid COVID-19 pandemic, monoclonal antibodies witnessed highest ever adoption in South and Central America regional market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The South & Central America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 5,584.2 Million |
| Market Size by 2028 | US$ 10,847.3 Million |
| CAGR (2021 - 2028) | 9.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Source
|
|
Regions and Countries Covered
|
|
| South and Central America | Brazil, Argentina, Rest of South and Central America |
| Market leaders and key company profiles |
|
The South and Central America Monoclonal Antibodies Market is valued at US$ 5,584.2 Million in 2021, it is projected to reach US$ 10,847.3 Million by 2028.
As per our report South and Central America Monoclonal Antibodies Market, the market size is valued at US$ 5,584.2 Million in 2021, projecting it to reach US$ 10,847.3 Million by 2028. This translates to a CAGR of approximately 9.9% during the forecast period.
The South and Central America Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Monoclonal Antibodies Market report:
The South and Central America Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Monoclonal Antibodies Market
